Startle Seizures and Diffuse Leukoencephalopathy After Resolution of Herpes Simplex Virus 1 Encephalitis in a Child

Andy Cheuk-Him Ng1, Janani Kassiri1, Helly R Goez1

  • 1University of Alberta, Edmonton, Canada.

Child Neurology Open
|April 1, 2022
PubMed

Insights

Herpes simplex virus 1 encephalitis can lead to delayed neurological issues. A child developed startle seizures and white matter brain injury months after initial infection and treatment.

Area of Science:

  • Neurology
  • Pediatric Neurology
  • Infectious Diseases

Background:

  • Herpes simplex virus 1 (HSV1) encephalitis is a serious neurological condition.
  • Prompt antiviral treatment is crucial for managing acute HSV1 encephalitis.
  • Long-term neurological sequelae of HSV1 encephalitis require further investigation.

Observation:

  • A 17-month-old boy, previously treated for HSV1 encephalitis, presented with new-onset startle seizures.
  • Neuroimaging revealed diffuse confluent leukoencephalopathy.
  • This specific combination of post-acute symptoms is not previously documented in HSV1 encephalitis literature.

Findings:

  • The study highlights a unique case of delayed neurological complications following HSV1 encephalitis.
  • The patient exhibited startle seizures and significant white matter abnormalities in the post-acute phase.
  • This suggests potential for late-onset neurological damage after HSV1 encephalitis.

Implications:

  • This case expands the understanding of potential long-term effects of HSV1 encephalitis.
  • It underscores the importance of monitoring for delayed neurological symptoms in children post-encephalitis.
  • Further research is needed to elucidate the mechanisms behind post-acute leukoencephalopathy and seizures in HSV1 encephalitis survivors.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
315
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
632
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
546
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
484
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
737